Sonoma Pharmaceuticals Inc. (SNOA)
NASDAQ: SNOA
· Real-Time Price · USD
3.95
0.01 (0.25%)
At close: Apr 29, 2025, 3:59 PM
3.87
-1.99%
After-hours: Apr 29, 2025, 06:40 PM EDT
Sonoma Pharmaceuticals Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal Care Revenue | 402K | 1.09M | 621K | 489K | 414K | 818K | 1M | 812K | 1.36M | 951K | 377K |
| Animal Care Revenue Growth | -63.22% | +76.01% | +26.99% | +18.12% | -49.39% | -18.61% | +23.77% | -40.16% | +42.69% | +152.25% | n/a |
| Human Care Revenue | 2.96M | 5.57M | 2.46M | 2.08M | 1.81M | 2.02M | 2.59M | 2.71M | 3.53M | 4.78M | 6.86M |
| Human Care Revenue Growth | -46.95% | +126.49% | +18.60% | +14.70% | -10.22% | -22.23% | -4.57% | -23.17% | -26.01% | -30.42% | n/a |
| Service And Royalty Revenue | 220K | 199K | 56K | 167K | n/a | 69K | 148K | 157K | n/a | n/a | n/a |
| Service And Royalty Revenue Growth | +10.55% | +255.36% | -66.47% | n/a | n/a | -53.38% | -5.73% | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2017 | Mar 31, 2016 |
|---|---|---|
| Latin America Revenue | 1.3M | 4.88M |
| Latin America Revenue Growth | -73.36% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.87M | 1.71M | 2.01M | 2.09M | 1.7M | 1.66M | 2.12M | 1.81M | 2.67M | 2.07M | 2.29M | 3.15M | 2.13M | 2.19M | 2.27M | 2.49M | 2.1M | 2.42M | 2.37M | 3.79M | 2.89M | 3.23M | 3.76M | 4.25M | 4.75M | 4.69M | 4.93M | 5.61M | 5.22M | 4.34M | 4.76M | 4.51M | 4.78M | 3.64M | 4.13M | 4.14M | 4.16M | 3.54M | 3.72M | 3.27M |
| Selling, General, and Administrative Revenue Growth | +9.91% | -15.13% | -3.92% | +22.78% | +2.47% | -21.57% | +17.07% | -32.08% | +28.93% | -9.93% | -27.19% | +47.63% | -2.73% | -3.43% | -8.71% | +18.57% | -13.15% | +2.07% | -37.46% | +30.98% | -10.35% | -14.18% | -11.59% | -10.41% | +1.22% | -4.95% | -11.99% | +7.40% | +20.34% | -8.94% | +5.63% | -5.75% | +31.32% | -11.79% | -0.36% | -0.31% | +17.59% | -4.87% | +13.60% | n/a |
| Research and Development Revenue | 427K | 506K | 470K | 409K | 601K | 536K | 325K | 201K | 400K | 200K | 6K | 4K | 26K | 10K | 84K | 130K | 33K | -85K | 476K | 483K | 248K | 270K | 338K | 327K | 451K | 390K | 350K | 476K | 349K | 368K | 382K | 350K | 487K | 379K | 360K | 441K | 486K | 412K | 467K | 374K |
| Research and Development Revenue Growth | -15.61% | +7.66% | +14.91% | -31.95% | +12.13% | +64.92% | +61.69% | -49.75% | +100.00% | +3233.33% | +50.00% | -84.62% | +160.00% | -88.10% | -35.38% | +293.94% | -138.82% | -117.86% | -1.45% | +94.76% | -8.15% | -20.12% | +3.36% | -27.49% | +15.64% | +11.43% | -26.47% | +36.39% | -5.16% | -3.66% | +9.14% | -28.13% | +28.50% | +5.28% | -18.37% | -9.26% | +17.96% | -11.78% | +24.87% | n/a |